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PMH29 NATIONAL ESTIMATES OF THE INPATIENT BURDEN OF PEDIATRIC BIPOLAR DISORDER
Berry E, Heaton PC, Kelton CM University of Cincinnati, Cincinnati, OH, USA OBJECTIVES: Bipolar disorder (BPD) is a debilitating recurrent chronic mental illness, characterized by cycling states of depression, mania, hypomania, and mixed episodes. The objectives of this study were to calculate national estimates of the annual burden of inpatient hospitalizations of children and adolescents with bipolar disorder (BPD); to describe and compare the burden across various patient characteristics, hospital characteristics, and key comorbidities associated with BPD; and to determine the independent effects of these factors on hospitalization costs. METHODS: Discharge observations for children whose primary diagnosis was BPD were collected from the Kids' Inpatient Database (KID). The burden was estimated as total number of days in the hospital, total charges, and total costs. Mean costs and charges were calculated and were broken down by patient and hospital characteristics and by the top six comorbidities found for BPD. Ordinary-least-squares regression models explaining cost were estimated for both 2003 and 2006 , and the models were compared by way of a Chow test. RESULTS: There were 39,136 (40,679) There is accumulating evidence of sub-therapeutic dosing of secondgeneration antipsychotics (SGAs), leading to suboptimal control of disease and higher overall treatment costs. Additional evidence is needed to better understand the clinical and economic outcomes of patients who receive clinically effective doses of SGAs. The objectives of this study were to distinguish patients receiving clinically recommended doses of SGAs and compare their medical care costs. METHODS: Patients with schizophrenia (N = 12,133) on an oral SGA (aripiprazole, olanzapine, quetiapine, risperidone or ziprasidone) were identified in Medicaid claims databases (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) from 8 states. Patients were followed for 18 months (6 month pre-index period during which patients did not receive an SGA, followed by a 12-month post-index utilization period to determine total costs). For patients on recommended dosing, costs were compared using a generalized linear model with a gamma distribution and log-link function, adjusting for baseline covariates (age, gender, race, pre-index costs, Charlson co-morbidity score, and specific psychiatric co-morbidities) with ziprasidone as the reference group. RESULTS: Of the 12,133 patients meeting study criteria 7,213 (59%) were taking clinically recommended doses by day 61 of their follow-up period. Patients on quetiapine had the lowest percentage at 37% (N = 1,057/2,869). Other results were aripiprazole 66%(N = 996/1515), olanzapine 65% (N = 1831/2828), risperidone 73% (N = 2807/3821), and ziprasidone, 47% (N = 522/1,100). When comparing groups of patients with recommended dosing, mental health-related costs (p = 0.006) and all-cause costs (p = 0.0005) were statistically higher for the quetiapine group compared to the ziprasidone group. CONCLUSIONS: Less than two-thirds of the Medicaid patients with schizophrenia who were started on an SGA were taking clinically recommended doses 2 months after their initial start. For patients using clinically recommended doses, those taking quetiapine had higher mental health-related costs and higher all-cause costs compared to patients taking ziprasidone. Included patients were aged 18-64 years, diagnosed with bipolar disorder, and newly treated with atypical antipsychotic medications. Patients were followed from treatment initiation to psychiatric hospitalization, medical hospitalization, discontinuation of index medication, loss to follow-up, or one year. Mean length of therapy was similar among the treatment groups. Generalized gamma regression compared inpatient costs between the groups. RESULTS: Among 19,176 bipolar patients, those treated with aripiprazole (n = 3,690) had a lower risk of hospitalization during their time on treatment (4.9%) compared to patients receiving ziprasidone (9.2% p < 0.001, n = 1515)), olanzapine (7.0% p < 0.001, n = 3038)), quetiapine (7.3% p < 0.001, n = 7936), and risperidone (7.2% p < 0.001, n = 2997). Fewer hospitalizations translated into lower per-patient-permonth psychiatric-related inpatient health care costs for patients receiving aripiprazole ($121) compared to those receiving other atypical antipsychotics (ziprasidone $249 p < 0.001, olanzapine ($203 p < 0.001), and quetiapine ($182 p < 0.006). Differences in hospitalization costs were not statistically significant between aripiprazole and risperidone ($159 p < 0.354). Total psychiatric-related health care costs were also significantly lower among aripiprazole patients than patients in each of the other treatment groups (p < 0.05). CONCLUSIONS: Among patients with bipolar disorder and newly treated with atypical antipsychotic medications, treatment with aripiprazole was associated with a lower risk of psychiatric hospitalization compared to patients receiving other atypical antipsychotic medications and lower psychiatricrelated inpatient costs compared to patients receiving ziprasidone, quetiapine, or olanzapine. These data are consistent with previous published findings studying the Ingenix integrated claims dataset. The results of this study suggest that aripiprazole may offer an economic advantage over other atypical antipsychotic medications in this patient population.
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